Please login to the form below
benign prostatic hyperplasia
This page shows the latest benign prostatic hyperplasia news and features for those working in and with pharma, biotech and healthcare.
CHMP backs Sanofi’s all-oral sleeping sickness drug
Italy’s Recordati also got a positive opinion for Silodosin Recordati (siloosin) a generic of its own Urorec drug used to treat benign prostatic hyperplasia (BPH).
Latest news
-
MS and cholesterol drugs picked for new UK rapid uptake push
Urolift for lower urinary tract symptoms of benign prostatic hyperplasia. The list is made up of seven ‘high-potential products’ with a strong evidence base that are already available to the
-
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB patients with benign prostatic hyperplasia, plus a third trial in patients with
-
Witty says Chinese bribery probe will impact GSK
Among other products, benign prostatic hyperplasia drug Avodart (dutasteride) had a good quarter, rising 12 per cent to £221m, while sales of Benlysta (belimumab) for lupus more than doubled to £38m
-
Astellas gets first OK for prostate drug Vesomni
Vesomni (formerly known as EC905) is a once-daily, fixed-dose combination of the antimuscarinic solifenacin and alpha blocker tamsulosin, which are both established treatments for men with benign prostatic hyperplasia
-
Actavis sales rise but profits slump as Lipitor effect recedes
benign prostatic hyperplasia, as well as the addition of Kadian, a modified-release morphine product attained as part of the Actavis acquisition.
More from news
Approximately 1 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
Interview: Giovanni Recordati
The company also has long expertise in urology. “We are currently rolling out a new drug for the treatment of benign prostatic hyperplasia and will soon be starting the last phase
-
Call to action for BPH
Campaign:ProState of the Nation. Timescale:February to October 2009. ProState of the Nation is an evidence-based report, bringing the issues of under-management and under-treatment of Benign Prostatic ... Benign Prostatic Hyperplasia (BPH) is a condition
-
Interview: Jorge Gallardo, Almirall
The year's sales evolution has benefited from the launches of new products Silodyx (for benign prostatic hyperplasia, licence from Recordati) and Conbriza (for osteoporosis, in co-promotion with Pfizer) in
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
